The recent run of good fortune for vaccine maker Novavax ( NASDAQ:NVAX ) continues. Following the major licensing deal with Sanofi ( NASDAQ:SNY ), Shah Capital has withdrawn its proxy campaign against the re-election of the company's directors at its annual meeting.